Navicyte Biotechnologies LLC

Navicyte Biotechnologies LLC has developed a proprietary targeted drug delivery platform designed to mimic natural immune cell trafficking. By functioning as a Trojan Horse, the technology delivers therapeutics directly to lymph nodes and immune-relevant tissues, allowing for precision targeting and enhanced drug efficacy. The platform is engineered to be compatible with a broad range of payloads, including oncology drugs, vaccines, immunotherapies, and nucleic acids. It offers tunable pharmacokinetics, allowing for drug release profiles ranging from hours to weeks, and is designed to be FDA and GMP-compatible with existing manufacturing pipelines.

This delivery technology is significant for developers looking to expand the therapeutic index of drugs, with preclinical models demonstrating up to a 500-fold improvement in efficacy and an 85% reduction in the required drug dose. The company focuses on addressing critical challenges in oncology, such as reducing the toxicity of chemotherapies, as well as improving treatments for HIV, tuberculosis, and vaccines. By facilitating precise access to lymphoid reservoirs and supporting in situ manufacturing, Navicyte aims to de-risk Phase I clinical trials and rescue shelved compounds. The team offers R&D resources to partners, including NIH investigators and pharmaceutical innovators, to evaluate therapeutic payloads for further translational development.